Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Germany’s Merck Appoints New Head of Biosimilars

By Drug Discovery Trends Editor | February 20, 2014

Merck announced that Simon Sturge will join the company from Boehringer Ingelheim effective March 1, to head the biosimilars unit. In his new role Sturge will report to Stefan Oschmann, member of Merck’s Executive Board and responsible for the company’s pharmaceutical businesses. 
 
The biosimilars unit is part of Merck’s pharmaceutical businesses alongside with Merck Serono, Consumer Health and Allergopharma. In early 2012, Merck decided to set up the biosimilars unit to develop molecules for oncology and inflammatory disorders through in-house research and development expertise in biologics, as well as through partnerships with other biosimilars players, such as Dr. Reddy’s Laboratories.
 
The unit is located in Canton de Vaud, Switzerland, where it makes use of Merck’s state-of-the-art biologics manufacturing facilities of Aubonne and Corsier sur Vevey with support from other European sites of the company.
 
With its investments in the evolving biosimilars market, Merck expects to benefit from rising demand for biotechnology solutions to address unmet medical needs and transform patients’ lives with innovative specialty medicines. 
 
“Merck has all the capabilities to compete in biosimilars and we expect significant growth of this market by the end of the decade,” said Oschmann. “Simon Sturge is ideally suited to develop our biosimilars unit and to be among the important players in this field.”  
 
Sturge joins from Boehringer Ingelheim where he, as head of biopharmaceuticals (including biosimilars), reported to the board of the company. Prior to Boehringer Ingelheim Sturge was CEO of Dutch biotech-company OctoPlus NV and before that position he acted as CEO of Vernalis. Sturge also held several roles of increasing seniority, from business development, marketing and operations, to positions as CEO at Lonza Biologics, Celltech Biologics and Astra. 
 
Sturge, a British native, holds a BSc Hons in Biology from the University of Sussex in the U.K. He was awarded UK Mediscience CEO of the year in 2005. 
 
Sturge succeeds Thierry Hulot, who created the biosimilars unit and took over responsibility for Global Manufacturing & Supply for the Merck Serono division at the end of last year.
 
Date: February 20, 2014
Source: Merck
 

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE